The Role of Hmg-CoA Reductase Inhibitors in Homozygous Familial Hypercholesterolemia

1996 ◽  
pp. 181-186
Author(s):  
A. David Marais ◽  
Jean C. Firth ◽  
Rossitza P. Naoumova ◽  
Gilbert R. Thompson
Keyword(s):  
Familial Hypercholesterolemia ◽  
Homozygous Familial Hypercholesterolemia ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Role of HMG-CoA Reductase Inhibitors in Neurological Disorders

Drugs ◽  
2007 ◽  
Vol 67 (15) ◽  
pp. 2111-2120 ◽  
Author(s):  
Allison B Reiss ◽  
Elzbieta Wirkowski
Keyword(s):  
Neurological Disorders ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

8 Role of HMG CoA Reductase Inhibitors and Proton Pump Inhibitors in the Prevention of Post ERCP Pancreatitis

2019 ◽  
Vol 114 (1) ◽  
pp. S4-S4 ◽  
Author(s):  
Mayssan Muftah ◽  
Rushikesh Shah ◽  
Sarah Cristofaro ◽  
Saurabh Chawla ◽  
Vaishali Patel ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Potential Use of HMG-CoA Reductase Inhibitors for Osteoporosis

2002 ◽  
Vol 36 (4) ◽  
pp. 671-678 ◽  
Author(s):  
Lolita M Cushenberry ◽  
Magaly Rodriguez de Bittner
Keyword(s):  
Bone Formation ◽  
Hmg Coa Reductase ◽  
Treatment Of Osteoporosis ◽  
Randomized Controlled Clinical Trials ◽  
Randomized Controlled ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Potential Use

OBJECTIVE: To review the current clinical data describing the effects of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in bone formation and reduction of fracture incidence and their potential use for osteoporosis. DATA SOURCES: English-language articles and abstracts were identified from a MEDLINE database search (1966–May 2001) that used the key words osteoporosis, HMG-CoA reductase inhibitors, and treatment. STUDY SELECTION AND DATA EXTRACTION: All the articles identified from the data sources were evaluated, and all information deemed relevant was included in this review. DATA SYNTHESIS: In the past, there has been considerable emphasis placed in the detection, prevention, and treatment of osteoporosis. New drug therapies have been introduced in the market aimed at decreasing bone loss and increasing bone formation, with the ultimate goal of decreasing fractures. Currently, there are a variety of agents available for the treatment of osteoporosis. A limited number of case—control studies have suggested that HMG-CoA reductase inhibitors (statins) may have the potential to reduce the risk of fractures by increasing bone formation, although other studies have failed to show a benefit in fracture reduction. The potential benefit of this therapy is still undetermined because of a lack of randomized, controlled, clinical trials and conflicting data. CONCLUSIONS: At this time, there are limited data on the role of statins in the treatment of osteoporosis. Practitioners must be cautious when using these agents over other proven conventional therapies. Randomized, controlled, clinical trials are needed to accurately determine the role of these agents in the treatment of osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document